The trial enrolled 320 non-squamous, non-small cell lung cancer patients who have failed treatment with EGFR tyrosine kinase inhibitor. Credit: Ed Uthman / Flickr (Creative Commons).

Akeso Biopharma has concluded subject enrolment in the Phase III clinical trial of its antibody, Ivonescimab (AK112), plus chemotherapy to treat epidermal growth factor receptor (EGFR)-mutant, locally advanced or metastatic, non-squamous non-small cell lung cancer (nsq-NSCLC).

The company commenced subject enrolment at the end of January this year.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

This double-blind, randomised, multicentre trial enrolled a total of 320 nsq-NSCLC patients who have failed treatment with an EGFR tyrosine kinase inhibitor (EGFR-TKI).

Progression-free survival (PFS) as evaluated by IRRC is the primary endpoint of the trial. 

 A PD-1/VEGF bi-specific antibody, Ivonescimab is developed by Akeso using Tetrabody technology.

It hinders the PD-1 attachment to PD-L1 and PD-L2 and also prevents VEGF binding to VEGF receptors. 

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

In October this year, the therapy received Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China, National Medical Products Administration (NMPA) to treat advanced NSCLC.

Ivonescimab previously received a similar designation for the first-line treatment of patients with NSCLC and positive PD-L1 expression.

The company is currently carrying out a Phase III trial of AK112 single agent compared with Pembrolizumab monotherapy as the first-line therapy for such patients. 

The therapy was earlier analysed in various trials for several stages of treatment of indications, including SCLC and NSCLC.

In October this year, the NMPA granted clearance for a Phase Ib/II trial of Ivonescimab plus Drebuxelimab (CD73, AK119) to treat advanced solid tumour patients.

In pre-clinical research, AK119 plus AK112 showed to have favourable in vivo pharmacodynamic activity and safety. 

A humanised monoclonal antibody of the company, Drebuxelimab could activate B-cells to induce immune responses against tumour antigens and viruses.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact